Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations.

[1]  I. Pandrea,et al.  Implications for Therapy , 2012 .

[2]  G. Plosker,et al.  Hexyl Aminolevulinate , 2012, Drugs.

[3]  B. Malavaud,et al.  Photodynamic Diagnosis in Non–Muscle-Invasive Bladder Cancer , 2010 .

[4]  T. Jonges,et al.  Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guérin immunotherapy and mitomycin C intravesical therapy. , 2010, European urology.

[5]  C. Stief,et al.  Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors. , 2009, Urology.

[6]  K. Thomas,et al.  Hexylaminolevulinate photodynamic diagnosis for multifocal recurrent nonmuscle invasive bladder cancer. , 2009, Journal of endourology.

[7]  K. Thomas,et al.  Bladder cancer: new TUR techniques , 2009, World Journal of Urology.

[8]  H. Grossman,et al.  1010 HEXVIX® FLUORESCENCE CYSTOSCOPY IMPROVES DETECTION AND RESECTION OF PAPILLARY BLADDER CANCER AND REDUCES EARLY RECURRENCE: A MULTICENTRE, PROSPECTIVE, RANDOMIZED STUDY , 2009 .

[9]  C. Stief,et al.  Positive urine cytology but negative white‐light cystoscopy: an indication for fluorescence cystoscopy? , 2009, BJU international.

[10]  P. Whelan.  Survival from bladder cancer in England and Wales up to 2001 , 2008, British Journal of Cancer.

[11]  B Rachet,et al.  Survival from bladder cancer in England and Wales up to 2001 , 2008, British Journal of Cancer.

[12]  K. Junker,et al.  [Photodynamic diagnostics in the urinary tract. Consensus paper of the Working Group for Oncology of the German Society for Urology]. , 2008, Der Urologe. Ausg. A.

[13]  D. Jacqmin,et al.  Photodynamic Diagnosis in Non-Muscle-Invasive Bladder Cancer , 2008 .

[14]  C. Stief,et al.  Routine Use of Photodynamic Diagnosis of Bladder Cancer: Practical and Economic Issues , 2008 .

[15]  R. Knuechel,et al.  Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high‐grade bladder cancer? A long‐term follow‐up of a randomized study , 2008, BJU international.

[16]  S. Denzinger,et al.  Photodynamische Diagnostik des Harnblasenkarzinoms , 2007 .

[17]  J Alfred Witjes,et al.  The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer , 2007, Nature Clinical Practice Urology.

[18]  H. Grossman,et al.  A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. , 2007, The Journal of urology.

[19]  Unyime Nseyo,et al.  A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. , 2007, The Journal of urology.

[20]  Maximilian Burger,et al.  Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. , 2007, European urology.

[21]  Bernhard Walter,et al.  Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. , 2007, Urology.

[22]  W. Otto,et al.  [Photodynamic diagnostic of superficial bladder carcinoma]. , 2007, Deutsche medizinische Wochenschrift.

[23]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[24]  M. Babjuk,et al.  Guidelines on TaT 1 ( Non-muscle invasive ) Bladder Cancer , 2006 .

[25]  Dietmar Schnorr,et al.  Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. , 2005, The Journal of urology.

[26]  Milan Jirsa,et al.  5‐aminolaevulinic acid‐induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer , 2005, BJU international.

[27]  Dieter Jocham,et al.  Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. , 2005, The Journal of urology.

[28]  J. Witjes,et al.  Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective Phase II study. , 2005, European urology.

[29]  M. Marberger,et al.  Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance? , 2005, European urology.

[30]  Vijay K Sangar,et al.  The economic consequences of prostate and bladder cancer in the UK , 2005, BJU international.

[31]  J. Witjes.  Bladder carcinoma in situ in 2003: state of the art. , 2004, European urology.

[32]  L. Kiemeney,et al.  Random bladder biopsies and the risk of recurrent superficial bladder cancer: a prospective study in 1026 patients , 1992, World Journal of Urology.

[33]  Jörg Schmidbauer,et al.  Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. , 2004, The Journal of urology.

[34]  Çağatay Göğüş,et al.  The significance of random bladder biopsies in superficial bladder cancer , 2004, International Urology and Nephrology.

[35]  Dieter Jocham,et al.  Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study. , 2003, The Journal of urology.

[36]  J. Rassweiler,et al.  Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. , 2002, The Journal of urology.

[37]  Thomas Filbeck,et al.  Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. , 2002, The Journal of urology.

[38]  Laurence Collette,et al.  Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. , 2002, European urology.

[39]  Dmitri Daniltchenko,et al.  FLUORESCENCE ENDOSCOPY WITH 5-AMINOLEVULINIC ACID REDUCES EARLY RECURRENCE RATE IN SUPERFICIAL BLADDER CANCER , 2001 .

[40]  C. Chapple.  Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction – Triumph: Design and Implementation , 2001, European Urology.

[41]  H O Dickinson,et al.  Cancer trends in England and Wales , 2000, BMJ : British Medical Journal.

[42]  J. Smith,et al.  Surgical management of noninvasive bladder cancer (stages Ta/T1/CIS). , 2000, The Urologic clinics of North America.

[43]  M. Droller,et al.  The natural history of bladder cancer. Implications for therapy. , 2000, The Urologic clinics of North America.

[44]  R. Sylvester,et al.  Significance of Bladder Biopsies in Ta,T1 Bladder Tumors: A Report from the EORTC Genito-Urinary Tract Cancer Cooperative Group , 1999, European Urology.

[45]  C. Smart.  Bladder cancer survival statistics. , 1990, Journal of occupational medicine. : official publication of the Industrial Medical Association.

[46]  A. Adelstein.  Studies on medical and population subjects. , 1976 .